Form4insider filings, from the source

SEC Form 4 · accession 0001193805-19-000067

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
James E Flynn
10% Owner
Period of report
Jan 11, 2019
Accepted (ET)
Jan 18, 2019 · 2:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2holding———4,481,788IThrough Deerfield Partners, L.P.
Common StockF1,F2holding———1,411,628IThrough Deerfield Special Situations Fund, L.P.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Cash-Settled Total Return SwapF3,F1,F2$7.00Jan 11, 2019J1A—Jan 19, 2022Common Stock1,8511I
Cash-Settled Total Return SwapF4,F1,F2,F5$6.969Jan 14, 2019J1A—Jan 19, 2022Common Stock61,7891I
Cash-Settled Total Return SwapF6,F1,F2,F7$6.931Jan 15, 2019J1A—Jan 19, 2022Common Stock48,2541I

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn. See footnote (1)